Anti Aging Medical Group Corp. Establishes Collaboration With AlphaRx and Leading Neurologists for Alzheimer's Disease

The i-Technology Media!	Register \| Log in

.NET · AJAX · CLOUD · ECLIPSE · FLEX · OPEN WEB · iPHONE · JAVA · LINUX · OPEN SOURCE · ORACLE · PBDJ · SEARCH · SILVERLIGHT · SOA · VIRTUALIZATION · WEB 2.0 · WIRELESS · XML

Comments

Improving the Efficiency of SOA-Based Applications

jhv1blz5 wrote: The article validated SOA as an IT architecture paradigm that can be leveraged in many ways. Taking data storage, scalability and application performance to a nifty level using SOA Application Grid infrastructure will no doubt enhance data and application performance on Oracle architecture platforms, it also has the promise of a cost effective and efficient IT delivery model. The very benefits of SOA.

Jul. 3, 2009 10:31 AM EDT

Cloud Computing | Virtualization
November 2 - 4
Register Today and SAVE !..

Did you read today's front page stories & breaking news?

Live Google News by SYS-CON!

Top Three Links You Must Click On

From the Wires

Anti Aging Medical Group Corp. Establishes Collaboration With AlphaRx and Leading Neurologists for Alzheimer's Disease

By: Marketwire .

Nov. 9, 2006 02:45 PM

TORONTO -- (MARKET WIRE) -- 11/09/06 -- Anti Aging Medical Group Corp. (PINKSHEETS: AAGM) is very pleased to announce that the company, inline with its new corporate strategy to become a leading specialty pharmaceutical company in the multi billion anti aging pharmaceutical market, has entered into the neuro-protection prescription drug market through a collaboration with AlphaRx Inc. (OTCBB: ALRX) and a group of leading neurologists.

Without getting into specifics at this point, the collaboration will focus on the development of selective neuroprotective compounds for the prevention and treatment of age-related Dementia indications such as Alzheimer's.

The collaboration has selected a well-known compound which in various pre-clinical studies have demonstrated low toxicity and proven to be highly effective in reducing brain inflammation, protecting neuronal cells, restoring cognitive function and preventing the development of Alzheimer's. This has not been a priority by the major pharmaceutical companies due to various formulation issues.

In addition, the collaboration believes its approach of using nanotechnology to deliver such compound through the blood brain barrier is viable and will attempt to screen 2 to 3 formulations in Alzheimer's animal models to determine the right dosage for human trials.

About Anti Aging Medical Group Corp.

We are a specialty pharmaceutical company focused on developing, acquiring and commercializing innovative and scientifically proven products that offer both health maintenance and appearance enhancing benefits to all of us. For more information about us please visit our website at www.aamgcorp.com.

FORWARD-LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

Distributed by Filing Services Canada and retransmitted by Market Wire

Contact:
Anti Aging Medical Group Corp.
E-mail: Email Contact

Published Nov. 9, 2006
Copyright © 2006 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.

About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.